Enovis Languishing Despite Respectable Performance

snoofek/iStock via Getty Images A Slight Step Back In The Last Quarter Q2 Results Will Likely Be Similar Enovis Should Have What It Needs To Compete The Outlook The Bottom Line The performance of mid-cap medical device company Enovis (NYSE:ENOV) is getting harder and harder for me to understand. As I've said in past articles, I've never really loved this business, and I've found some of management's projections to be overly optimistic, but I do think there is a solid orthopedic device business here, and I f ...